TORONTO, ON--(Marketwired - Sep 17, 2013) - Axxess Pharma Inc. (PINKSHEETS: AXXE), a specialty pharmaceutical and nutritional supplements company, today announced it has signed an Agreement for its acquisition of the assets of Revive Bioscience Inc. a leading Canadian OTC healthcare company, the terms of the deal remain private.
Revive Bioscience Inc.'s assets include revenues, product inventory, established sales channels, an attractive IP portfolio; including a best-selling, OTC pain relief formula and a number of other proprietary formulas.
Revive has a national distribution of products in Canada, through GNC and independent retail stores, and expects to add other large retail outlets later this year. The products Revive developed will be sold in mass retail stores across Canada (currently in market), USA and Mexico.
Further, the company has an exclusive world-wide license with one of the top sporting brands in the world. This license provides access to a global distribution network, including 20,000+ retailers. The branded products are endorsed by current athletes from the NFL, NHL and UFC.
Revive also brings a number of key operators to Axxess Pharma with extensive experience in retail and online sales. This will benefit all of the products now controlled by Axxess Pharma.
Dr. Daniel Bagi, President of Axxess Pharma Inc., stated: "We are extremely pleased and excited to announce this acquisition of Revive. Both sides have been working long and hard to finalize this acquisition, which will instantly add revenues to Axxess Pharma's bottom line. We believe we can very quickly grow sales significantly working with Revive's team through added marketing efforts. They have great products which are widely recognized. We expect this acquisition will facilitate access to capital and enable a rapid ramp-up of sales for major revenue growth in the near term."
For more information, please visit www.axxesspharmainc.com, or contact Investor Relations at (973) 351-3868.
About Axxess Pharma Inc.:
Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, to optimal health management through improved nutritional supplements.
Revive BioScience Inc.:
Revive BioScience Inc. is an international organization which develops and markets medically proven, all-natural pain relief products, including OTC analgesics, topical analgesics, supplements and hot & cold therapy products. Revive's flagship product is the patented all-natural topical pain relief formula, free of chemical binders and additives, that absorbs quickly into the skin providing fast, effective pain relief. Revive's patented formula has 15 years of history, medical studies and numerous endorsements.
GNC Holdings, Inc.:
GNC Holdings, Inc., headquartered in Pittsburgh, PA, is a leading global specialty retailer of health and wellness products, including vitamins, minerals, and herbal supplement products, sports nutrition products and diet products, and trades on the New York Stock Exchange under the symbol "GNC."
As of June 30, 2013, GNC has more than 8,300 locations, of which more than 6,200 retail locations are in the United States (including 969 franchise and 2,189 Rite Aid franchise store-within-a-store locations) and franchise operations in 55 countries (including distribution centers where retail sales are made). The Company -- which is dedicated to helping consumers Live Well -- has a diversified, multi-channel business model and derives revenue from product sales through company-owned retail stores, domestic and international franchise activities, third party contract manufacturing, e-commerce and corporate partnerships. GNC's broad and deep product mix, which is focused on high-margin, premium, value-added nutritional products, is sold under GNC proprietary brands, including Mega Men®, Ultra Mega®, Total Lean™, Pro Performance®, Pro Performance® AMP, Beyond Raw®, and under nationally recognized third party brands.
Safe Harbor Statement:
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.